These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36907614)

  • 41. Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.
    Camaschella C; Nai A
    Br J Haematol; 2016 Feb; 172(4):512-23. PubMed ID: 26491866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beta-thalassemia and the advent of new interventions beyond transfusion and iron chelation.
    Chauhan W; Shoaib S; Fatma R; Zaka-Ur-Rab Z; Afzal M
    Br J Clin Pharmacol; 2022 Aug; 88(8):3610-3626. PubMed ID: 35373382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
    Shash H
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pyruvate kinase activators: targeting red cell metabolism in thalassemia.
    Kuo KHM
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):114-120. PubMed ID: 38066911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
    Rivella S; May C; Chadburn A; Rivière I; Sadelain M
    Blood; 2003 Apr; 101(8):2932-9. PubMed ID: 12480689
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiac complications in beta-thalassemia: From mice to men.
    Kumfu S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Exp Biol Med (Maywood); 2017 Jun; 242(11):1126-1135. PubMed ID: 28485683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transferrin receptor 2 (Tfr2) genetic deletion makes transfusion-independent a murine model of transfusion-dependent β-thalassemia.
    Di Modica SM; Tanzi E; Olivari V; Lidonnici MR; Pettinato M; Pagani A; Tiboni F; Furiosi V; Silvestri L; Ferrari G; Rivella S; Nai A
    Am J Hematol; 2022 Oct; 97(10):1324-1336. PubMed ID: 36071579
    [TBL] [Abstract][Full Text] [Related]  

  • 48. β-Thalassemia.
    Origa R
    Genet Med; 2017 Jun; 19(6):609-619. PubMed ID: 27811859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene.
    May C; Rivella S; Chadburn A; Sadelain M
    Blood; 2002 Mar; 99(6):1902-8. PubMed ID: 11877258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systematic Literature Review of the Burden of Disease and Treatment for Transfusion-dependent β-Thalassemia.
    Betts M; Flight PA; Paramore LC; Tian L; Milenković D; Sheth S
    Clin Ther; 2020 Feb; 42(2):322-337.e2. PubMed ID: 31882227
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia.
    Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F
    J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating miRNAs and tissue iron overload in transfusion-dependent β-thalassemia major: novel predictors and follow-up guide.
    El-Khazragy N; Matbouly S; Hanna DH; Mahran NA; Mostafa SA; Abdelrehim BA; Farouk YK; Abuelela S
    Ann Hematol; 2021 Dec; 100(12):2909-2917. PubMed ID: 34432101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beta-thalassemia: is cure still a dream?
    Hodroj MH; Akiki N; Bou-Fakhredin R; Taher AT
    Minerva Med; 2023 Dec; 114(6):850-860. PubMed ID: 37534831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New strategies to target iron metabolism for the treatment of beta thalassemia.
    Oikonomidou PR; Casu C; Rivella S
    Ann N Y Acad Sci; 2016 Mar; 1368(1):162-8. PubMed ID: 26919168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
    Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S
    Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ineffective Erythropoiesis: Anemia and Iron Overload.
    Gupta R; Musallam KM; Taher AT; Rivella S
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):213-221. PubMed ID: 29458727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Iron overload in thalassemia: different organs at different rates.
    Taher AT; Saliba AN
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
    Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
    Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
    Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
    Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.